Company: XAIR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001493152-25-005678
Chunk: 119

Company: Beyond Air, Inc.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part II, Item 8
Chunk 119
---
 uncertainties and other important factors that may
cause our actual results, performance or achievements to be materially different from any future results, performance or achievements
express or implied by the forward-looking statements.

In
some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “expect,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negative of these terms or other similar conditional expressions. The forward-looking
statements in this Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations
and projections about future events and financial trends that we believe may affect our business, financial condition and results of
operations. These forward-looking statements speak only as of the date of this Form 10-Q and are subject to a number of important factors
that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under
the sections in this Form 10-Q titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition
and Results of Operations,” Item 1A “Risk Factors” contained in our most recently filed Annual Report on Form 10-K,
as well as the following:

    ●
    our
    ability to successfully commercialize our LungFit® PH system in the U.S.;

    ●
    our
    ability to successfully commercialize CE Certificate of Conformity to CE mark LungFit® in the European Union (the “EU”)
    and international markets;

    ●
    our
    expectation to incur losses for the next few years;

    ●
    our
    ability to predict accurately the demand for our products, and products under development and to develop strategies to address markets
    successfully;

    ●
    the
    possibility that products may contain undetected errors or defects or otherwise not perform as anticipated;

    ●
    the
    anticipated development of markets we sell our products into and the success of our products in these markets;

    ●
    our
    future capital needs and our need to raise additional funds;

    ●
    our
    ability to build a pipeline of product candidates and develop and commercialize our approved products;

    ●
    our
    ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary certifications